Presentations
Investor Presentation
Presentations
October 18, 2018
3rd Phase 3 Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris
January 17, 2018
Phase 3 Open-label Safety and Patient Satisfaction of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris
October 15, 2017
Phase 3 Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris
October 15, 2017
Pharmacokinetic Evaluation of FMX101, Topical Minocycline Foam, for the Treatment of Acne Vulgaris
January 18, 2017
Phase 2 Randomized Trial of FMX103, Topical Minocycline Foam, for the Treatment of Papulopustular Rosacea
February 14, 2016
Phase 2 Randomized Trial of FMX101, Topical Minocycline Foam, for the Treatment of Acne Vulgaris